Here is an excerpt from DECN's SEC filing of 3/30/20 where it gives a pretty transparent accounting of why and how it decided to get into the COVID-19 testing and based on what science.
Now someone can claim it's all a lie and all fantasy, smoke and mirrors, but if YOU want to make a judgement, judge what the company states and not what others state about it:
The company’s GenUltimate TBG product makes use of impedance technology to measure the number of red blood cells in a patient blood sample, information relevant to a glucose measurement in that same patient. Mr. Berman, the company’s CEO, became convinced that a similarly configured device could be built for the determination of Covid-19.
As quickly as it could the company engaged Matthew Musho, PhD (holder or collaborator in 32 patents published in parallel fields) and his wife Leslie to assist in the design of a testing method and device for the measurement of Covid-19. Matthew Musho patents
The company also engaged FDA practice counsel to prepare the company and its new product for submission for emergency use authorization (EUA) by the FDA. Counsel, already familiar with the company’s products and technologies, understood almost immediately what the company was trying to achieve and during the last week in February counsel contacted the FDA. This contact was made a day or two prior to the FDA’s eased guidance for EUA, published on February 27, 2020. A subsequent further easing of FDA past policy appeared in a March 16, 2020 guidance policy. The specifications guidelines set down by Mr. Berman, for creating this Covid-19 testing device and its important chemistry, were that the test must be measured on the company’s existing Precise or Avantage glucometers, because they were completed products, having been tested to great length, and now to be adapted for detection of Covid-19 instead of whole blood glucose.
In addition, the resulting chemistry would necessarily run using a patients (small sample of) whole blood taken from a finger prick, and later defined as 1-2 microliters (a small drop on a finger tip), and perform the test and provide a result in one minute or less (later redefined as 15 seconds or less), with at least a 95% accuracy. Mr. Berman believed this device was capable of 97-98% accuracy. Three alternative designs were provided and given to the company on March 2. Two of the designs were diagrammed by Mathew Musho, PhD, the third design by a chemist and engineer from The Bio in Korea. The chosen of the three alternative product designs would bear the trade name GenViro! Swift. The company then set to work, along with Matthew Musho, PhD (“Musho”), to evaluate the designs, keeping in mind the desired specifications of the DECN CEO and product Program Director, which included availability of components without wait time, time to market (assuming FDA EUA), whether the chosen method was applicable to use in point of care and at-home environments, time of assay from commencement of test and until result, size of the blood sample, and finally cost to produce. Given the company’s experience in working with biosensors and with electrode technology, the design review process took less time than originally expected. The entire process took 13 days. The last of these days used to determine which of the two Musho specifications was to be chosen. The design provided by The Bio was discarded because it could not be read on the existing company meter technology, and therefore would require additional development. At the end of this process, the company chose to produce the product shown in the illustrations, the second of the two Musho alternative versions, but shortly thereafter to begin work on the other Musho specification, to be used as a confirmation tool.
Silence the non-sense and judge for yourselves. Do you think he made the whole narrative up? Do you think he was dreaming? If so sell any stock you have. If not, hold on tight.
AI
